{
  "@context": "http://id.who.int/icd/contexts/contextForLinearizationEntity.json",
  "@id": "http://id.who.int/icd/release/11/2024-01/mms/2019647878",
  "parent": [
    "http://id.who.int/icd/release/11/2024-01/mms/773550674"
  ],
  "browserUrl": "https://icd.who.int/browse/2024-01/mms/en#2019647878",
  "code": "2A52",
  "source": "http://id.who.int/icd/entity/2019647878",
  "classKind": "category",
  "postcoordinationScale": [
    {
      "@id": "http://id.who.int/icd/release/11/2024-01/mms/2019647878/postcoordinationScale/hasManifestation",
      "axisName": "http://id.who.int/icd/schema/hasManifestation",
      "requiredPostcoordination": "false",
      "allowMultipleValues": "AllowAlways",
      "scaleEntity": [
        "http://id.who.int/icd/release/11/2024-01/mms/322466810"
      ]
    }
  ],
  "title": {
    "@language": "en",
    "@value": "Myeloid or lymphoid neoplasms with FGFR1 abnormalities"
  },
  "definition": {
    "@language": "en",
    "@value": "Hematologic neoplasms characterised by the rearrangement of the FGFR1 gene, resulting in translocations with an 8p11 breakpoint. Patients may present with a myeloproliferative neoplasm, acute myeloid leukaemia, lymphoblastic lymphoma/leukaemia of T or B-cell lineage, or acute leukaemia of mixed phenotype."
  },
  "indexTerm": [
    {
      "label": {
        "@language": "en",
        "@value": "Myeloid or lymphoid neoplasms with FGFR1 abnormalities"
      }
    }
  ]
}